FindTrial
Sign In

Multi-omics study of short-term remission induced by intensive short-term insulin therapy in patients with newly diagnosed type 2 diabetes mellitus

Multi-omics study of short-term remission induced by intensive short-term insulin therapy in patients with newly diagnosed type 2 diabetes mellitus

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075644
Enrollment
Unknown
Registered
2023-09-11
Start date
2023-09-11
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Diabetes remission group and diabetes non remission group:NA

Sponsors

The Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Newly diagnosed type 2 diabetic patients with with significant hyperglycemia or hyperglycemia-related symptoms who are hospitalized in the endocrinology department beginning July 2023 and require intensive insulin treatment.

Exclusion criteria

Exclusion criteria: Type 1 diabetes mellitus, secondary diabetes mellitus, GADA antibody-positive patients, patients with severe and acute complications of diabetes mellitus, patients with severe infectious diseases, patients using drugs that affect glucose metabolism such as corticosteroids, patients who are pregnant or breastfeeding, patients with severe liver or renal insufficiency.

Design outcomes

Primary

MeasureTime frame
Metabolomics;miRNAomics;—

Countries

China

Contacts

Public ContactLongyi Zeng

The Third Affiliated Hospital of Sun Yat-Sen University

zengly@mail.sysu.edu.cn+86 138 0295 8625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026